Scientists at MIT have engineered antibody–bottlebrush conjugates that expand antibody-drug conjugate (ADC) payload flexibility by enabling higher drug-to-antibody ratios and inclusion of lower potency compounds. This modular design overcomes limitations of classical ADCs, potentially improving therapeutic indices and clinical efficacy. Preclinical data demonstrate favorable pharmacokinetics and tumor targeting, suggesting a new frontier in precision oncology drug delivery. This advancement promises to broaden the scope of payload chemistries and improve outcomes in targeted cancer therapies.